Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.84 |
| ▸ | PTGDR | Q13258 | 18/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.72 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4517822 | 0.92 | PTGDR2 (0.86) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL4513300 | 0.91 | PTGDR2 (1.00) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL4500992 | 0.91 | PTGDR2 (0.88) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL4507381 | 0.90 | PTGDR2 (0.85) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL13816502 | 0.87 | PTGDR2 (0.81) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL4506179 | 0.87 | PTGDR2 (0.80) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL6951622 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL29362700 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL29371844 | 0.83 | PTGDR2 (1.00) | PTGDR2PTGDRABCC3ABCC4ABCB11 | |
| SCHEMBL4501444 | 0.83 | PTGDR2 (0.86) | PTGDR2PTGDRABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085891-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | PTGDR2 200/4885PTGDR 185/4885ABCC3 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.